Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
SERVICE ANALYSE DSC ET TGA Activery offre aussi le service d analyse thermique (analyse DSC et TGA) en externalisation. Nous effectuons l analyse thermique pour différents produits chimies, polymères, cosmétiques et , spécialement, pour produits pharmaceutiques come des principes actives ou for...
In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine
Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.
In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.
| Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease. |
|
|
|
|
UCSB Develops Nanoparticle That Attacks Artery Plaque Invention Proved to Effectively Eliminate Blockages in Mice By Rachel Reeves Tuesday, June 9, 2009 UCSB researchers have developed a nanoparticle capable of attacking atherosclerotic plaques, which accumulate in the arteries and can cause heart attack or stroke. The researchers' conclusions appear in a recent issue of the scientific journal Proceedings of the National Academies of Science. The team aims to use the newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease. Atherosclerotic plaque is a leading cause of cardiovascular disease, which is responsible for a third of deaths in the United States each year. In order to develop the nanoparticle that targets these plaques, the researchers induced the plaques in mice by keeping them on high-fat diets, and injected the mice with nanoparticles called micelles, or lipid-based molecules. They found that the micelles were in fact targeting the correct areas of the plaques. Matthew Tirrell, dean of the UCSB College of Engineering, explained the utility and efficacy of the nanoparticles that have been recently developed. "We think that self-assembled micelles [of peptide amphiphiles] of the sort we have used in this work are the most versatile, flexible nanoparticles for delivering diagnostic and therapeutic biofunctionality in vivo," he said in a press release. "The ease with which small particles, with sufficiently long circulation times and carrying peptides that target and treat pathological tissue, can be constructed by self-assembly is an important advantage." The research was funded by a grant from the National Heart, Lung and Blood Institute of the National Institutes of Health. UCSB researchers include: Tirrell, Erkki Ruoslahti, Venkata Ramana Kotamraju, Kunal Gujraty and David Peters of the Burnham Institute for Medical Research; Mark Kastantin of the Department of Chemical Engineering; and Priya P. Karmali of the Cancer Research Center, Burnham Institute for Medical Research in La Jolla. |